-
Unichem Laboratories appoints Gunjan Gupta as CFO
Unichem Laboratories has appointed Gunjan Gupta as its Chief Financial Officer (CFO), effective from May 9, 2023. Gupta will be responsible for the company's financial planning, budgeting, and reporting, as well as managing its treasury and investor relations functions.
-
Unichem Laboratories receives USFDA approval for generic version of Revlimid
Unichem Laboratories has received approval from the US Food and Drug Administration (USFDA) for its generic version of Revlimid (lenalidomide), a drug used to treat multiple myeloma and myelodysplastic syndromes. The approval marks a significant milestone for Unichem, as it expands its portfolio of oncology products.
-
Unichem Laboratories' Q3FY23 net profit rises 14% to Rs 304 crore
Unichem Laboratories reported a 14% year-on-year increase in its net profit to Rs 304 crore for the third quarter of fiscal 2023 (Q3FY23), driven by strong growth in its domestic and international businesses.
-
Unichem Laboratories Q3 net profit rises 12.4% to Rs 347 crore
Drug firm Unichem Laboratories on Monday reported a 12.38 per cent rise in its consolidated net profit to Rs 346.95 crore for the quarter ended December 31, 2022.
-
Unichem Laboratories launches generic version of Xarelto in India
Unichem Laboratories has launched the generic version of Xarelto, a blockbuster anti-clotting drug, in the Indian market.
-
Unichem Laboratories gets US FDA approval for generic version of Nexium
Unichem Laboratories has received approval from the US Food and Drug Administration (FDA) for its generic version of Nexium, a heartburn drug.
